List of Excipients in Branded Drug XULANE

« Back to Dashboard

Generic Drugs Containing XULANE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	norelgestromin and ethinyl estradiol	0378-3340	CROSPOVIDONE
Mylan Pharmaceuticals Inc	norelgestromin and ethinyl estradiol	0378-3340	DIPROPYLENE GLYCOL
Mylan Pharmaceuticals Inc	norelgestromin and ethinyl estradiol	0378-3340	MINERAL OIL
Mylan Pharmaceuticals Inc	norelgestromin and ethinyl estradiol	0378-3340	OLEYL ALCOHOL
A-S Medication Solutions	norelgestromin and ethinyl estradiol	50090-1683	CROSPOVIDONE

What are the Most Frequently-Used Excipients in XULANE?

# Of NDCs	Excipient
2	CROSPOVIDONE
2	DIPROPYLENE GLYCOL
2	MINERAL OIL
2	OLEYL ALCOHOL

XULANE Excipient Strategy and Commercial Opportunities in Transdermal Contraception

Last updated: August 27, 2026

XULANE is a norelgestromin/ethinyl estradiol transdermal contraceptive system that uses a drug-in-adhesive matrix. Its commercial value is tied to adhesive performance, dose delivery, skin tolerability, manufacturing reproducibility, and regulatory substitutability. The principal excipient opportunity is not a simple ingredient replacement. It is the development of an improved transdermal adhesive platform that can maintain hormone delivery while reducing detachment, irritation, residue, and manufacturing variability.

What is XULANE and how is it formulated?

XULANE delivers norelgestromin and ethinyl estradiol through the skin for once-weekly contraception. The system releases approximately 150 micrograms of norelgestromin and 35 micrograms of ethinyl estradiol per day under labeled conditions.[1]

The product is a multilayer transdermal system:

Component	Function	Commercial relevance
Backing layer	Protects the drug matrix and controls handling	Affects flexibility, occlusion, moisture resistance, and comfort
Drug-in-adhesive layer	Contains the active ingredients and pressure-sensitive adhesive	Primary excipient and product-performance risk
Release liner	Protects the adhesive before use	Affects stability, peelability, and packaging compatibility
Polyisobutylene	Pressure-sensitive adhesive component	Drives adhesion, residue, and skin-contact performance
Crospovidone	Inactive matrix component listed for XULANE	May affect matrix structure and drug release
Polyester materials	Used in patch construction	Affect mechanical strength and manufacturing yield

The FDA label identifies polyisobutylene and crospovidone as inactive ingredients in the XULANE system.[1] The product is manufactured as a matrix patch rather than as a reservoir system. This design reduces the risk of liquid or gel leakage but makes adhesive composition, coating uniformity, and drug diffusion central to product quality.

Which excipients protect XULANE’s commercial performance?

Polyisobutylene is the core adhesive excipient. It provides pressure-sensitive adhesion without requiring a separate liquid reservoir. Its molecular-weight distribution, tack, cohesive strength, and interaction with the backing and release liner affect:

• Initial adhesion after application
• Wear over seven days
• Edge lifting and complete detachment
• Adhesive residue on skin
• Skin stripping during removal
• Drug diffusion through the matrix
• Long-term stability

Crospovidone has a less visible but important role. In a transdermal matrix, it can influence the physical structure of the adhesive layer, active-ingredient dispersion, moisture response, and release behavior. A change in particle size, grade, surface area, or supplier can alter coating rheology and dissolution behavior even when the nominal excipient concentration remains unchanged.

The commercial implication is that excipient sameness alone does not guarantee equivalent patch performance. Critical material attributes include:

1. Polyisobutylene molecular weight and viscosity profile.
2. Crospovidone particle-size distribution and moisture content.
3. Active-ingredient particle size and polymorphic form.
4. Adhesive-layer thickness and coat-weight uniformity.
5. Backing-film permeability and mechanical properties.
6. Release-liner silicone chemistry and peel force.
7. Residual solvent profile, where applicable.
8. Drug content uniformity across the coated web.

How does XULANE’s excipient strategy affect generic development?

A generic or follow-on XULANE product must establish pharmaceutical equivalence and bioequivalence under the applicable FDA pathway. For a transdermal system, the development burden extends beyond assay and dissolution. Product performance can involve adhesion studies, skin irritation, sensitization, wear time, adhesion percentage, peel strength, and systemic pharmacokinetic equivalence.

The key formulation challenge is balancing three competing requirements:

Objective	Excessive performance can cause	Insufficient performance can cause
Adhesion	Painful removal, skin stripping, residue	Detachment and contraceptive failure risk
Cohesion	Poor conformability and edge lifting	Excessive residue or cohesive failure
Drug diffusion	Dose dumping or high exposure	Subtherapeutic exposure
Occlusion	Higher flux and irritation	Lower delivery and poor adhesion
Moisture resistance	Reduced breathability	Premature lifting during bathing or exercise

For an ANDA applicant, the lowest-risk strategy is generally to reproduce the reference product’s excipient architecture and critical quality attributes as closely as possible. A materially different adhesive or matrix may require more extensive comparative performance data and could create regulatory questions about inactive-ingredient safety and product equivalence.

What formulation patents and intellectual-property barriers affect XULANE?

XULANE’s commercial position originated from the transdermal contraceptive technology associated with Ortho Evra and norelgestromin/ethinyl estradiol delivery. Historic patent protection covered aspects of the patch, hormone delivery, adhesive matrix, and contraceptive use. The commercial relevance of those patents has declined as core patent terms expired and generic competition entered the market.

The current IP risk is more likely to arise from incremental technology than from the basic XULANE composition. Potentially relevant patent categories include:

• Low-residue pressure-sensitive adhesives
• Silicone or acrylic adhesive systems
• Hormone-stabilizing excipient combinations
• Reduced-area patches
• High-flux or low-dose transdermal systems
• Improved wear-time systems
• Skin-barrier modifiers
• Manufacturing processes for continuous web coating
• Packaging systems that limit hormone loss or crystallization
• Alternative hormone combinations or dosing schedules

A company developing a new patch should conduct a freedom-to-operate review across composition, device construction, manufacturing process, and method-of-use claims. A formulation that avoids XULANE’s specific polyisobutylene/crospovidone configuration may still implicate broader adhesive or transdermal delivery patents.

When does XULANE lose exclusivity?

XULANE is a small-molecule transdermal product, not a biologic. Biosimilar exclusivity rules do not apply. Market entry is governed primarily by FDA approval pathways, listed patents, regulatory exclusivity, and commercial contracting.

The relevant exclusivity categories are:

Exclusivity type	Relevance to XULANE
New chemical entity exclusivity	Unlikely to protect the current product because the active ingredients were previously known
Three-year clinical-investigation exclusivity	Could apply to certain qualifying supplemental approvals, but is not the principal barrier to established XULANE competition
Five-year NCE exclusivity	Not the expected framework for this product
Orphan exclusivity	Not relevant to contraception
Pediatric exclusivity	Could extend applicable exclusivity by six months if granted
Patent protection	Depends on Orange Book-listed patents and enforceable claims
First generic exclusivity	May apply to an eligible first ANDA applicant, depending on filing history

FDA approved XULANE under NDA 204697 for Mylan Pharmaceuticals, now associated with Viatris’ portfolio.[1] The original branded transdermal contraceptive was Ortho Evra. Generic and authorized-generic competition has reduced the practical exclusivity of the product class.

An exact current exclusivity date requires a contemporaneous FDA Orange Book and FDA exclusivity-record review. The commercial point is clear: XULANE is an established, multisource-type opportunity rather than a protected first-in-class asset.

What is the Orange Book status of XULANE?

The Orange Book is the primary FDA source for approved products, therapeutic equivalence evaluations, patents submitted for listing, and certain exclusivity information.[2]

XULANE’s Orange Book analysis should focus on:

• NDA 204697
• Active ingredient: norelgestromin and ethinyl estradiol
• Dosage form: transdermal system
• Route: transdermal
• Listed patents, if any remain active
• Therapeutic-equivalence codes for approved competitors
• NDA and ANDA approval status
• Any patent-use-code limitations

For a commercial diligence process, the Orange Book must be checked against FDA’s current electronic records. Patent listings can change through delisting, expiration, statutory updates, or corrections. Historical patent expiration alone does not establish the current regulatory status.

Which companies are challenging or competing with XULANE?

Competition comes from three directions.

Generic transdermal systems

Generic manufacturers can compete on price while using an adhesive system designed to achieve pharmaceutical equivalence and bioequivalence. The main entry barriers are:

• Adhesion performance
• Manufacturing scale
• Hormone handling and containment
• Stability through the labeled shelf life
• Patch uniformity
• FDA review of transdermal equivalence
• Payer substitution and pharmacy stocking

Alternative contraceptive patches

Twirla, levonorgestrel/ethinyl estradiol transdermal system, is a competing contraceptive patch with a different active-ingredient combination and product design. It targets the same broad weekly-patch convenience segment but is not therapeutically identical to XULANE.[3]

XULANE delivers norelgestromin and ethinyl estradiol. Twirla delivers levonorgestrel and ethinyl estradiol at a lower nominal estrogen delivery rate. The products therefore compete commercially but are not interchangeable solely because both are weekly patches.

Non-patch contraceptives

Oral contraceptives, vaginal rings, long-acting reversible contraceptives, injectables, and implants compete for the same contraceptive use case. Their commercial advantages include lower application burden, longer duration, lower visibility, or reduced dependence on weekly adherence.

How does XULANE compare with other contraceptive patches?

Attribute	XULANE	Twirla
Active hormones	Norelgestromin and ethinyl estradiol	Levonorgestrel and ethinyl estradiol
Administration	Weekly transdermal patch	Weekly transdermal patch
Adhesive strategy	Drug-in-adhesive matrix using polyisobutylene and crospovidone	Distinct formulation and patch technology
Regulatory relationship	Established product with generic competition	Separate branded product and patent estate
Main commercial advantage	Familiarity, established distribution, and lower-cost positioning	Product differentiation and alternative hormone profile
Main formulation risk	Detachment, residue, skin tolerability, and generic substitution	Adhesion, wear, tolerability, and commercial adoption

XULANE’s excipient strategy supports a lower-cost, established-product position. Twirla’s opportunity is differentiation through formulation and product design rather than direct substitution.

What excipient innovations could create commercial opportunities?

Silicone pressure-sensitive adhesives

Silicone adhesives can improve skin tolerability and reduce residue in some systems. They may also provide better performance on sensitive skin. Their disadvantages include higher material cost, possible changes in hormone solubility, and the need to establish compatibility with the active ingredients.

Acrylic adhesives

Acrylic systems offer tunable adhesion and broad formulation flexibility. They can be engineered for different tack, peel, and shear profiles. The main risks are residual monomers, sensitization potential, and changes in drug crystallization or diffusion.

Hybrid adhesive systems

A hybrid matrix combining polyisobutylene with silicone or acrylic chemistry could target better wear and lower residue. Such a change would create a meaningful development program because the adhesive is also part of the drug-delivery matrix.

Crystallization-control excipients

Norelgestromin and ethinyl estradiol must remain uniformly dispersed throughout the adhesive layer. Polymer modifiers, solubilizers, or selected plasticizers may reduce crystallization and improve dose uniformity. Any new excipient must be justified for dermal exposure and evaluated for its impact on drug flux.

Skin-interface modifiers

Moisture-management materials, low-irritancy tackifiers, and barrier-compatible excipients could improve comfort and adhesion during bathing, exercise, or perspiration. These technologies have commercial value if they reduce premature detachment without increasing dermatitis.

Smaller-area systems

A higher-flux matrix or improved permeation strategy could reduce patch size. A smaller patch may improve patient acceptance, but it can also increase local irritation and make manufacturing tolerances more demanding.

What manufacturing and IP barriers affect a XULANE follow-on?

Continuous web coating is a major operational barrier. The manufacturer must control coat weight, active distribution, adhesive rheology, web tension, drying conditions, and die-cutting. Small variations can produce visible defects, dose variation, edge lifting, or inconsistent release.

Hormone-containing adhesive webs also create containment and cleaning challenges. Manufacturing controls must address:

• Potent-compound exposure
• Cross-contamination
• Coating-line recovery
• Environmental controls
• Waste handling
• In-process weight checks
• Visual inspection
• Packaging integrity
• Finished-product adhesion testing

A differentiated entrant can seek patent protection for the complete system, not only the excipient. Stronger claim positions may cover a defined adhesive composition combined with specified hormone loading, patch area, release profile, and adhesion performance.

What generic entry risks exist for XULANE?

The principal generic-entry risks are operational rather than scientific.

Risk	Likely effect
Failure to match adhesion	FDA deficiency, recall risk, or loss of pharmacy confidence
Hormone crystallization	Dose nonuniformity and release failure
Skin irritation	Lower persistence and payer or prescriber resistance
Limited manufacturing scale	Supply interruptions and weak gross margins
Weak patent clearance	Paragraph IV litigation or delayed launch
Poor substitution status	Reduced automatic pharmacy substitution
Limited payer access	Low prescription conversion despite approval
Reference-product shortage	Difficulty completing comparative studies

A Paragraph IV challenge would be relevant only if an applicant certifies that an Orange Book-listed patent is invalid, unenforceable, or not infringed. Under the Hatch-Waxman framework, the NDA holder may file patent litigation within the statutory period, potentially triggering a 30-month stay of approval under applicable conditions.[4] For an established patch with limited remaining patent barriers, the economic value of a Paragraph IV strategy depends on whether the listed patent claims cover commercially meaningful formulation or manufacturing features.

What is the revenue opportunity for XULANE excipients and follow-on products?

The most attractive opportunities are platform-based rather than single-product excipient sales.

Excipient supplier opportunity

An excipient supplier can pursue:

• Low-residue polyisobutylene grades
• High-purity transdermal acrylic adhesives
• Medical-grade silicone adhesives
• Controlled-particle-size crospovidone
• Hormone-compatible tackifiers
• Release liners with defined peel profiles
• Backing films optimized for moisture and flexibility

The supplier’s strongest position comes from regulatory support, multiple approved customers, and a documented change-control package.

Finished-product opportunity

A follow-on manufacturer can compete through:

• Lower acquisition cost
• Improved adhesion
• Reduced visible residue
• Better skin tolerability
• Smaller patch dimensions
• Private-label or authorized-generic distribution
• Medicaid and managed-care contracting
• International registration using a common technical platform

Licensing opportunity

Licensing targets include adhesive patents, transdermal coating know-how, validated manufacturing processes, and regional commercialization rights. A license with a proven adhesive platform can reduce development time but may increase royalty burden and constrain supplier changes.

How strong is the XULANE patent estate?

The core product estate is weaker as a current exclusivity barrier than a newly approved transdermal product’s estate because the underlying contraceptive patch technology has been commercialized for many years. The stronger patent opportunities now lie in improvements:

• Adhesive composition
• Reduced-irritation delivery
• Improved seven-day wear
• Dose stabilization
• Smaller patch area
• Manufacturing methods
• Packaging and shelf-life protection
• Alternative hormone combinations

A strong improvement patent should link composition to measurable product performance. Broad claims to a generic adhesive class are more vulnerable to prior-art challenges. Narrow claims with defined polymer ratios, hormone loading, release characteristics, and adhesion outcomes may be more defensible but can be easier to design around.

Key Takeaways

• XULANE is a weekly norelgestromin/ethinyl estradiol drug-in-adhesive patch.
• Polyisobutylene is the principal pressure-sensitive adhesive excipient; crospovidone is also listed as an inactive ingredient.[1]
• Commercial differentiation depends on adhesion, residue, tolerability, drug uniformity, and manufacturing scale.
• Generic development is technically more demanding than an oral solid dosage form because adhesive and skin-performance attributes are central to equivalence.
• Biosimilar risk does not apply because XULANE is a small-molecule product.
• The most valuable IP opportunities concern improved adhesives, reduced patch size, skin tolerability, drug stabilization, and manufacturing control.
• Twirla is a competing weekly contraceptive patch but uses different active ingredients and is not automatically interchangeable with XULANE.
• Current patent, Orange Book, and Paragraph IV conclusions require review of the FDA’s active records for the relevant filing date.

FAQs

Can XULANE use a silicone adhesive instead of polyisobutylene?

Yes, but replacing polyisobutylene would materially change the drug-delivery matrix. The developer would need to establish comparable drug stability, release, adhesion, skin tolerability, and systemic exposure.

Is crospovidone essential to XULANE’s contraceptive effect?

Crospovidone is not an active contraceptive ingredient. It can still be important to matrix structure, coating behavior, drug dispersion, and release performance. Removing or substituting it may require substantial formulation and equivalence work.

Does an XULANE generic need to use the same excipients?

Not necessarily. A generic may use different inactive ingredients if it satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, safety, and product performance. Transdermal differences can create a higher review burden than ordinary oral formulations.

Can a smaller XULANE patch be patented?

Potentially. Patentability would depend on novelty, nonobviousness, written description, enablement, and the specific combination of patch area, adhesive composition, hormone loading, delivery rate, and performance characteristics.

Are XULANE and Twirla therapeutically interchangeable?

No. They contain different progestins and are separate FDA-approved products. Pharmacy substitution depends on the applicable FDA therapeutic-equivalence determination and state substitution law.

References

1. U.S. Food and Drug Administration. (2014). XULANE (norelgestromin and ethinyl estradiol) transdermal system prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2020). Twirla (levonorgestrel and ethinyl estradiol) transdermal system prescribing information.
4. U.S. Food and Drug Administration. (2015). Patent listing and certification procedures under the Drug Price Competition and Patent Term Restoration Act.